Literature DB >> 6805630

Meningococcal disease in Scandinavia.

H Peltola, K Jónsdóttir, A Lystad, C J Sievers, I Kallings.   

Abstract

Scandinavia (Denmark, Finland, Iceland, Norway, and Sweden) comprises with mutual borders and 22.3 million inhabitants an area where the socioeconomic and cultural conditions are similar. Epidemic diseases, such as meningococcal infection, might therefore be expected to be uniformly distributed. An epidemiological study in the 10-year period 1970-9 shows, however, remarkable differences in the incidence, age, and serogroup and type distribution, as well as in the general dynamics of the disease. Three epidemics, two caused by different serotypes of group B (Norway and Iceland) and one by group A (Finland) occurred within the observation period. The annual overall incidence was generally around 3/100 000 but increased from fivefold (Finland) to eightfold (northern Norway) during epidemics. The epidemic strains caused infection in over 3000 patients and the loss of at least 250 lives. The overall case fatality rate was 8.6% (range 4.1-13.7%). Men were more susceptible and had a worse prognosis than women of the same age group. The group A epidemic in Finland was influenced by a large vaccination campaign, but this possibility was not feasible in the two other epidemics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6805630      PMCID: PMC1498539          DOI: 10.1136/bmj.284.6329.1618

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  33 in total

1.  Field trial of the efficacy of a previously proposed regimen using minocycline and rifampin sequentially for the elimination of meningococci from healthy carriers.

Authors:  L F Devine; R B Pollard; P E Krumpe; E S Hoy; R E Mammen; C H Miller; R O Peckinpaugh
Journal:  Am J Epidemiol       Date:  1973-06       Impact factor: 4.897

2.  Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method.

Authors:  C E Frasch; S S Chapman
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

3.  [Current aspects of epidemic cerebrospinal meningitis in Rumania].

Authors:  F Mihalcu; O Paşolescu; V Coban; G Cuciureanu; S Dumitrescu
Journal:  Arch Roum Pathol Exp Microbiol       Date:  1972-03

4.  Meningococcal disease, 1965.

Authors:  H A Feldman
Journal:  JAMA       Date:  1966-05-02       Impact factor: 56.272

5.  [Sulfa resistant meningococcus in Sweden--occurrence, vaccination and chemoprophylaxis].

Authors:  I Moberg
Journal:  Lakartidningen       Date:  1975-03-05

6.  [Microbiologic characteristics of meningococcal infections in Moscow during years of a periodic rise in incidence (1968--1971)].

Authors:  N N Kostiukova; T K Mironova; E V Leshchinskaia
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1974

7.  Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping.

Authors:  R Gold; J L Winklehake; R S Mars; M S Artenstein
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Prevention of meningococcal disease by group C polysaccharide vaccine.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; H Schneider; C Harkins
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

9.  A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

Authors:  M H Wahdan; F Rizk; A M el-Akkad; A A el-Ghoroury; R Hablas; N I Girgis; A Amer; W Boctar; J E Sippel; E C Gotschlich; R Triau; W R Sanborn; B Cvjetanović
Journal:  Bull World Health Organ       Date:  1973-06       Impact factor: 9.408

10.  Meningococcal infections in Bolton, 1971-74.

Authors:  J S Farries; W Dickson; E Greenwood; T R Malhotra; J D Abbott; D M Jones
Journal:  Lancet       Date:  1975-07-19       Impact factor: 79.321

View more
  12 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease.

Authors:  D A Caugant; L O Frøholm; K Bøvre; E Holten; C E Frasch; L F Mocca; W D Zollinger; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

3.  Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

4.  A laboratory review of meningococcal infections in the west of Ireland.

Authors:  G Corbett-Feeney
Journal:  Ir J Med Sci       Date:  1996 Oct-Dec       Impact factor: 1.568

5.  Meningococcal infections in Scotland 1972-82.

Authors:  R J Fallon; W M Brown; W Lore
Journal:  J Hyg (Lond)       Date:  1984-10

6.  Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide.

Authors:  I Vodopija; Z Baklaic; P Hauser; P Roelants; F E André; A Safary
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

7.  A one year survey of meningococcal disease in Italy.

Authors:  T Stroffolini; F Rosmini; C M Curianò
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

8.  Meningococcal disease in South Australia: incidence and serogroup distribution 1971-1980.

Authors:  D Hansman
Journal:  J Hyg (Lond)       Date:  1983-02

9.  Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83.

Authors:  L Spanjaard; P Bol; S de Marie; H C Zanen
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

Review 10.  Meningococcal meningitis and carriage in western Zaire: a hypoendemic zone related to climate?

Authors:  J S Cheesbrough; A P Morse; S D Green
Journal:  Epidemiol Infect       Date:  1995-02       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.